Eli Lilly and Company
NYSE:LLYDrug Manufacturers - General
-$10.54 today
- Market cap
- $1.30T
- Beta
- 0.52
- P/E (TTM)
- 39.0
- EPS (TTM)
- $28.26
- Dividend yield
- 0.59%
Volume 2.58M
Average 3.19M
LLY Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Eli Lilly and CompanyNYSE: LLY
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q2 FY2026 capital expenditures of $2.93B (cash outflow) rose 62.6% year over year, ahead of the -26.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 26.1% from the prior quarter. Over 3 fiscal years it compounded at +38.0% a year.
Context
- Capital expenditures amounted to 12.0% of revenue in FY2025, up 0.8 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +62.6% holds above the trailing-twelve-month pace of -26.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (7.84B) USD
- Year-over-year change
- -55.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.84B) | -55.0% |
| FY2024 | 2024-12-31 | (5.06B) | +31.6% |
| FY2023 | 2023-12-31 | (7.39B) | -147.6% |
| FY2022 | 2022-12-31 | (2.99B) | -50.9% |
| FY2021 | 2021-12-31 | (1.98B) | — |
Capital Expenditures vs competitors
How LLY compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -26.9% is the 7th highest of 9, against a peer median of +5.5%.
- Capital expenditures amounts to 10.1% of revenue for LLY, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 84.09B DKK | +40.3% | +82.8% | 25.5% | |
| LTM Jun 2026 | $8.03B USD | -26.9% | +38.0% | 10.1% | |
| LTM Sep 2026 | $5.57B USD | +8.6% | +6.4% | 5.6% | |
| LTM Sep 2026 | $4.01B USD | -28.0% | +31.9% | 6.5% | |
| LTM Jun 2026 | $3.9B USD | +2.4% | -2.1% | 5.9% | |
| LTM Jun 2026 | $2.57B USD | -35.5% | -11.4% | 4.6% | |
| LTM Jun 2026 | €2.52B EUR | — | -1.8% | 5.2% | |
| LTM Jun 2026 | $2.42B USD | -12.1% | -6.7% | 3.8% | |
| LTM Jun 2026 | $2.3B USD | +63.6% | +25.7% | 6.0% | |
| LTM Jun 2026 | $1.3B USD | +24.2% | +20.4% | 2.0% | |
| Peer median (excluding LLY) | — | +5.5% | +6.4% | 5.6% | |
Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B |
| Depreciation & Amortization | 1.55B | 1.52B | 1.53B | 1.77B | 2B |
| Deferred Income Tax | (802.3M) | (2.19B) | (2.34B) | (2.68B) | (1.71B) |
| Stock-Based Compensation | 342.8M | 371.1M | 628.5M | 645.6M | 626M |
| Change in Working Capital | (1.01B) | (800K) | (3.06B) | (5.39B) | (8.09B) |
| Accounts Receivables | (1.28B) | (299.6M) | (2.45B) | (2.16B) | (7B) |
| Inventory | (235.9M) | (599.7M) | (1.43B) | (2.51B) | (4.67B) |
| Accounts Payables | (1.01B) | 1.33B | 4.27B | 2.61B | 10.19B |
| Other Working Capital | 1.52B | (433.2M) | (3.45B) | (3.33B) | (6.61B) |
| Other Non-Cash Items | 1.71B | 1.63B | 2.24B | 3.88B | 3.35B |
| Operating Cash Flow | 7.37B | 7.59B | 4.24B | 8.82B | 16.81B |
| Capital Expenditures | (1.98B) | (2.99B) | (7.39B) | (5.06B) | (7.84B) |
| Acquisitions (Net) | (747.4M) | (327.2M) | (1.04B) | (947.7M) | (661M) |
| Purchases of Investments | (1.01B) | (707.6M) | (829M) | (775.8M) | (645M) |
| Sales of Investments | 847.4M | 463.6M | 700.3M | 522.5M | 964M |
| Other Investing Activities | (644.3M) | (1.34B) | (2.53B) | 303.1M | (2.79B) |
| Investing Cash Flow | (2.87B) | (3.76B) | (7.15B) | (9.3B) | (10.97B) |
| Debt Repayment | 501.4M | (62M) | 8.65B | 8.9B | 8.05B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (1.25B) | (1.5B) | (750M) | (2.5B) | (4.11B) |
| Dividends Paid | (3.09B) | (3.54B) | (4.07B) | (4.68B) | (5.38B) |
| Other Financing Activities | (295.9M) | (308.9M) | (335M) | (490.6M) | (772M) |
| Financing Cash Flow | (4.13B) | (5.41B) | 3.5B | 1.23B | (2.21B) |
| Effect of Forex Changes | (205.7M) | (167.6M) | 168.6M | (296.7M) | 372M |
| Net Change in Cash | 161.4M | (1.75B) | 751.6M | 449.8M | 4B |
| Free Cash Flow | 5.39B | 4.6B | (3.15B) | 3.76B | 8.97B |
Eli Lilly and Company
NYSE:LLY
Intrinsic Alpha fair value
Locked
Current Price
$1,382.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.